|
|||||
|
|
Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort |
|
| Authors: | Lorelei A Mucci Yudi Pawitan Francesca Demichelis Katja Fall Jennifer R Stark Hans-Olov Adami Swen-Olof Andersson Ove Andrén Anna S Eisenstein Lars Holmberg Wei Huang Philip W Kantoff Sven Perner Meir J Stampfer Jan-Erik Johansson Mark A Rubin |
| Affiliation: | Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. lmucci@hsph.harvard.edu |
| Abstract: | Tumor molecular markers hold promise to distinguish potentially lethal from indolent prostate cancer and to guide treatment choices. A previous study identified a nine-gene molecular signature in tumors associated with prostate-specific antigen relapse after prostatectomy. We examined this molecular model in relation to prostate cancer death among 172 men with initially localized disease. We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer. |
| Keywords: | |